Sign In
Buy KYMR
$73.21
+1.92 (+2.69%)
At Close: Jun 03, 2026
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
07:00am, Wednesday, 27'th May 2026
WATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines
Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases
Kymera Therapeutics, Inc. (KYMR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
02:50pm, Tuesday, 12'th May 2026
Kymera Therapeutics, Inc. (KYMR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
11:00am, Tuesday, 12'th May 2026
SHAREHOLDER ALERT: Purcell and Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) PR N
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
10:00am, Tuesday, 12'th May 2026
NEW YORK, May 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kymera Therapeutics, Inc. (NASDAQ: KYMR) on behalf of the company's shareholders. The investigation
Pre-Market Stock Futures: Futures are trading higher on Wednesday as news of an impending end to the Iran war is sending oil prices dramatically lower. This news comes after a bounce-back Tuesday that
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
07:00am, Wednesday, 06'th May 2026
WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
07:00am, Tuesday, 05'th May 2026
KT-579 demonstrated activity comparable or superior to approved and clinically active therapies in preclinical IBD models
KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration
03:10pm, Friday, 01'st May 2026
Kymera Therapeutics tops Q1 revenue estimates on strong Gilead collaboration, as pipeline advances and KT-200 milestone deal boost outlook.
Kymera Therapeutics, Inc. (KYMR) Q1 2026 Earnings Call Transcript
01:51pm, Thursday, 30'th Apr 2026
Kymera Therapeutics, Inc. (KYMR) Q1 2026 Earnings Call Transcript
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates
09:35am, Thursday, 30'th Apr 2026
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to a loss of $0.82 per share a year ago.
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
07:00am, Thursday, 30'th Apr 2026
KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to K
B. Metzler seel. Sohn & Co. AG Purchases New Holdings in Kymera Therapeutics, Inc. $KYMR
03:48am, Monday, 27'th Apr 2026
B. Metzler seel. Sohn and Co. AG purchased a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) in the fourth quarter, according to its most recent disclosure with the Securities and Exch
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
07:00am, Thursday, 23'rd Apr 2026
WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicine
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells $374,185.23 in Stock
04:36am, Sunday, 19'th Apr 2026
Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) Director Bruce Booth sold 4,159 shares of the stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $89
